Tarsus Pharmaceuticals Valuation
| TARS Stock | USD 46.52 0.40 0.85% |
At this time, the company appears to be undervalued. Tarsus Pharmaceuticals has a current Real Value of $53.25 per share. The regular price of the company is $46.52. Our model measures the value of Tarsus Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 38.23 M, return on equity of -0.6, and Operating Margin of (0.52) % as well as reviewing its technical indicators and probability of bankruptcy.
Undervalued
Today
Please note that Tarsus Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Tarsus Pharmaceuticals is based on 3 months time horizon. Increasing Tarsus Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tarsus stock is determined by what a typical buyer is willing to pay for full or partial control of Tarsus Pharmaceuticals. Since Tarsus Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tarsus Stock. However, Tarsus Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.52 | Real 53.25 | Hype 47.02 |
The intrinsic value of Tarsus Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Tarsus Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Tarsus Pharmaceuticals helps investors to forecast how Tarsus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tarsus Pharmaceuticals more accurately as focusing exclusively on Tarsus Pharmaceuticals' fundamentals will not take into account other important factors: Tarsus Pharmaceuticals Total Value Analysis
Tarsus Pharmaceuticals is at this time projected to have valuation of 1.55 B with market capitalization of 1.79 B, debt of 31.73 M, and cash on hands of 245.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tarsus Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.55 B | 1.79 B | 31.73 M | 245.36 M |
Tarsus Pharmaceuticals Investor Information
About 91.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.28. Tarsus Pharmaceuticals recorded a loss per share of 3.75. The entity had not issued any dividends in recent years. Based on the key indicators related to Tarsus Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Tarsus Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in February.Tarsus Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Tarsus Pharmaceuticals has an asset utilization ratio of 6.57 percent. This implies that the Company is making $0.0657 for each dollar of assets. An increasing asset utilization means that Tarsus Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Tarsus Pharmaceuticals Ownership Allocation
The majority of Tarsus Pharmaceuticals outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tarsus Pharmaceuticals to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tarsus Pharmaceuticals. Please pay attention to any change in the institutional holdings of Tarsus Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Tarsus Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 17.45 M. Net Loss for the year was (135.89 M) with profit before overhead, payroll, taxes, and interest of 107.2 M.About Tarsus Pharmaceuticals Valuation
The stock valuation mechanism determines Tarsus Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Tarsus Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tarsus Pharmaceuticals. We calculate exposure to Tarsus Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tarsus Pharmaceuticals's related companies.Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. Tarsus Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.
Tarsus Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Tarsus Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.4 M |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.